Press Releases2017-09-13T20:17:34+00:00

Press Releases

In Psoriasis, Use of the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights

After several years on the market, the majority of US dermatologists report that Cosentyx has lost its advantage over Taltz as the first IL-17 inhibitor on the market; with increased penetration of Taltz for the treatment of psoriatic arthritis, will rheumatologists follow suit? Download Report Overview EXTON, Pa., April 17, 2019 /PRNewswire/ — Spherix Global Insights has been tracking the evolution of the US psoriatic arthritis (PsA) market on a quarterly basis since 2015 via the RealTime Dynamix™: Psoriatic Arthritis (US) report series. The PsA landscape has been experiencing large-scale change as rheumatologists continue to adopt alternate mechanism of action (MOA) [...]

April 18, 2019|

Preferential First-Line Use of Biogen’s Tecfidera and Continued Uptake of Merck KGaA’s Mavenclad Drives the Significant Increase in Oral Disease-Modifying Therapy Class Share in the European Multiple Sclerosis Market Over the Past Year

Assuming approval and dependent upon the label in Europe, Novartis’ Mayzent should be well positioned for strong adoption in active secondary progressive multiple sclerosis and transitioning relapsing-remitting multiple sclerosis, although low unaided awareness of the latter patient type may hamper uptake without a focused educational strategy, according to the prelaunch assessment in a new report from Spherix Global Insights Download Report Overview EXTON, Pa., April 10, 2019 ―Self-reported oral disease-modifying therapy (DMT) class share has increased significantly over the past year in the EU multiple sclerosis (MS) market, pulling share from the injectable DMT classes. In the current wave of [...]

April 10, 2019|

US Gastroenterologists Project Near-Term Growth of Takeda’s Entyvio and Janssen’s Stelara for the Treatment of Crohn’s Disease, while Anticipated Increased Adoption of Pfizer’s Xeljanz in Ulcerative Colitis is Likely to Interrupt Entyvio’s Trajectory

According to a recent report by Spherix Global Insights, US gastroenterologists’ (n=99) adoption of Xeljanz for the treatment of ulcerative colitis continues to be positive, but looming safety concerns could spell trouble for the first-in-class JAK inhibitor. Download Report Overview EXTON, Pa., March. 26, 2019 /PRNewswire/ — At approximately eight months post-launch, Pfizer’s Xeljanz is continuing to have success penetrating the US ulcerative colitis (UC) market, according to Spherix Global Insights’ quarter one update of RealTime Dynamix™: Inflammatory Bowel Disease (US).  While the recent growth of Xeljanz is largely sourced by an expanding user base (as opposed to patient base), and as [...]

March 26, 2019|

US Rheumatologists Show Continued Uptake of Eli Lilly’s Olumiant for the Treatment of Rheumatoid Arthritis, Though Safety Concerns and Lack of Experience in the Market Withhold Full Potential

According to a recent report by Spherix Global Insights, Eli Lilly’s Olumiant and Regeneron’s Kevzara enjoy continued uptake, though rising safety concerns associated with the JAK inhibitor class may blunt Olumiant’s trajectory Download Report Overview EXTON, Pa., March. 25, 2019 /PRNewswire/ — Overall brand share among biologic/JAK-treated patients in the US rheumatoid arthritis (RA) market has remained relatively stagnant over the past year, according to Spherix Global Insights’ latest quarterly wave of RealTime Dynamix™: Rheumatoid Arthritis (US). Unsurprisingly, the established TNFs, primarily AbbVie’s Humira and Amgen’s Enbrel, still dominate the market, though surveyed rheumatologists (n=101) report a slight decrease in share of [...]

March 25, 2019|

Spherix Global Insights’ Quarterly Update on the US Migraine Prevention Market Reveals Best-In-Class Sales and Medical Affairs Support as the Driving Force Behind Teva’s Ajovy Early Launch Success

Ajovy’s lack of an autoinjector may not be an obstacle for the brand as neurologists and migraine specialists report a sizeable percentage of patients treated with Amgen/Novartis’ Aimovig and Eli Lilly’s Emgality choosing to use the prefilled syringe option over the heavily promoted Aimovig SureClick and Emgality Pen devices. Download Report Overview EXTON, Pa., March 25, 2019 /PRNewswire/―With the 2018 launches of the new class of anti-calcitonin gene-related peptide (CGRP) therapies, specifically Amgen/Novartis’ Aimovig, Teva’s Ajovy, and Eli Lilly’s Emgality, for the prevention of migraine, the preventive treatment rate of chronic migraine has increased significantly compared to six months ago. In [...]

March 25, 2019|

Two Years After Launch of Genentech’s Ocrevus, US Neurologists Report a Significant and Persistent Increase in the Treatment of Patients with Primary Progressive Multiple Sclerosis

According to a new report from Spherix Global Insights, Novartis’ Mayzent is anticipated to grow the size of the secondary progressive multiple sclerosis segment in the United States, decreasing the influence of the relapsing remitting multiple sclerosis segment on market dynamics Download Report Overview EXTON, Pa., March 12, 2019 ―Expanding adoption of Genentech’s Ocrevus among US neurologists has significantly and persistently increased the rate of disease-modifying therapy (DMT) treatment among patients with primary progressive multiple sclerosis (PPMS) compared to two years ago.  In the current wave of the ongoing quarterly  RealTime Dynamix™: Multiple Sclerosis (US) report series, neurologists (n=99) report [...]

March 12, 2019|